<Anchor>

Kolon, the company that made the drug, ordered the US to inspect it after the cell was found to have the tumor-inducing cells in the human body approved as the world's first gene therapy drug. In order to find out what ingredients are being distributed in the domestic market, intermediate tests have confirmed that there are tumor-inducing cells.

First, it is the sole report of Cho Dongchan, a medical journalist.

<Reporter>

Kolon Life Science sent the products of Invo Company, which is in circulation in the domestic market, to 'W' in America, and commissioned the ingredients.

Kolon officials said they received a mid-term result today (8th), and that the same tumor-causing cells as those found in the US have been identified, and the final report will be released on the 15th.

Invivo is composed of one liquid with only cartilage cells and two liquids with cartilage cells and growth factors.

The tumor-causing cells were found in two liquids, two of which were made from one cell bank and sold to the domestic market, and the US clinical trial was conducted, so Kolon said it expects the same results.

In the case of invoices sold in Korea, it is confirmed that kidney cells other than chondrocytes have been incorporated, and the authorities decide whether or not to cancel the license.

Although the drug store is considering withdrawing permission from SBS, it is unclear that the conclusions may differ depending on whether the cells were originally changed or changed in the middle.

[Kang, Seok-Yeon / Director, Biotechnology and Herb Medicine Department: We have difficulty in making a final decision right now. For example, now that we have a probation, test results, or something like this, we have to judge synthetically. "

There are also opinions that it is difficult to keep the license because it is difficult to see the same ingredient as the licensed medicine, and there is a possibility that the drug maker will worry about alternatives such as changing the items considering the wavelength.

(Image editing: Yumira)